Please login to the form below
aclidinium
This page shows the latest aclidinium news and features for those working in and with pharma, biotech and healthcare.
Circassia seeks shift to AIM after failing LSE criteria
The Oxford-based company is buying US commercial rights to AstraZeneca’s chronic obstructive pulmonary disease (COPD) medicine Tudorza (aclidinium bromide), a drug that the two companies have partnered since 2017. ... Duaklir (aclidinium/formoterol)
Latest news
-
Circassia exits allergy R&D after placebo effect strikes again
Circassia also recently formed a partnership with AstraZeneca (AZ) for the development and commercialisation of two chronic obstructive pulmonary disease (COPD) medicines - Tudorza (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) in
-
GSK's triple COPD therapy tops Symbicort in phase III trial
These include GSK's Relvar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide), as well as Novartis' Ultibro (glycopyrronium/indacaterol), AZ's own Duaklir (aclidinium bromide/formoterol fumarate) and Boehringer
-
GSK brings forward triple COPD therapy filing in US
GSK is jostling for market share with other two-drug combinations, however, including Novartis' Ultibro (glycopyrronium/indacaterol), AstraZeneca's Duaklir (aclidinium bromide/formoterol fumarate) and Boehringer Ingelheim's Spiolto
-
Boehringer bags FDA approval for Spiriva-based combo
AstraZeneca is also bringing its aclidinium bromide/formoterol fumarate product -sold in Europe as Duaklir - through the latter stages of development.
-
GSK sees COPD future in triple therapy
Duaklir (formoterol fumarate and aclidinium bromide) jostling for market share.
More from news
Approximately 1 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Interview: Jorge Gallardo, Almirall
We now have five R&D projects about to start or already in phase III and we are intending to register another two projects in 2011: aclidinium bromide for chronic obstructive
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- New medical communications agency BOLDSCIENCE launches
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- Moderna inks R&D agreements with Vertex and Chiesi
- FDA approves Roche’s Actemra COVID-19 trial
- Shionogi's Gram-negative antibiotic launches in the UK
- Live Webinar: Medical Modeling in Virtual Reality
- Live Webinar: Telemedicine & the Digitization of Medicine post COVID-19
- Havas Health & You Launches Behind the Mask, a Global Research Initiative to Document Health Experiences During the COVID-19 Pandemic and Beyond
- AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain
- BMS eyes approval for second Opdivo combo in kidney cancer
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
